Bicalutamide – Uses, Dosage, Side Effects, Interaction Bicalutamide is a nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury. Bicalutamide is a synthetic, nonsteroidal antiandrogen. Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04) Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantiomers. Bicalutamide binds to the androgen receptor. Mechanism of Action Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Bicalutamide is a nonsteroidal antiandrogen that is structurally and pharmacologically related to flutamide and nilutamide. Bicalutamide inhibits the action of androgens by competitively blocking nuclear androgen receptors in target tissues such as the prostate, seminal vesicles, and adrenal cortex; blockade of androgen receptors in the hormone-sensitive tumor cells may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis. Bicalutamide is a selective antiandrogen with no androgenic or progestational activity in various animal models. The relative binding affinity of bicalutamide at the androgen receptor is more than that of nilutamide and approximately 4 times that of hydroxyflutamide, the active metabolite of flutamide. Common pharmacologic therapies for prostate cancer (ie, gonadotropin-releasing hormone [GnRH] analogs, nonsteroidal antiandrogens) when used as monotherapy initially result in increased serum testosterone concentrations, which may limit the effects of the drugs. Androgen receptors in the hypothalamus are blocked by bicalutamide, which disrupts the inhibitory feedback of testosterone on luteinizing hormone (LH) release, resulting in a temporary increase in the secretion of LH; the increase in LH stimulates an increase in the production of testosterone. As GnRH analogs have potent GnRH agonist properties, testicular steroidogenesis continues during the first few weeks after initiating therapy. However, the combination of orchiectomy or GnRH analog therapy to suppress testicular androgen production and an antiandrogen to block the response of remaining adrenal androgens provides maximal androgen blockade. Concomitant administration of antiandrogens such as bicalutamide in patients initiating therapy with a GnRH analog can inhibit initial androgenic stimulation and potential exacerbation of symptoms (e.g., bone pain, urinary obstruction, liver pain, impending spinal cord compression) that may occur during the first month of GnRH analog therapy. Indications For treatment (together with surgery or LHRH analog) of advanced prostatic cancer. Bicalutamide is a nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury. Bicalutamide/ 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Use in Cancer Bicalutamide is approved to treat: Prostate cancer that has metastasized (spread to other parts of the body). It is used with a type of drug called a luteinizing hormone-releasing hormone agonist. Bicalutamide is also being studied in the treatment of other types of cancer. Contraindications are allergic to bicalutamide or any ingredients of the medication have early-stage (localized) prostate cancer and would otherwise undergo watchful waiting diabetes anemia a type of inflammation of the lung called interstitial pneumonitis damage to the liver and inflammation liver problems abnormal liver function tests pregnancy Dosage Strengths: 50 mg Prostate Cancer In combination with an LHRH analog: 50 mg orally once a day (morning or evening) Side Effects The Most Common hot flashes or flushing bone, back, or pelvic pain muscle weakness muscle or joint pain headache shortness of breath increased blood pressure swelling of the hands, feet, ankles, or lower legs cough constipation nausea vomiting abdominal pain diarrhea gas change in weight (loss or gain) loss of appetite dizziness pain, burning, or tingling in the hands or feet difficulty sleeping feeling of uneasiness or dread rash sweating inability to get or keep an erection need to urinate frequently during the night bloody urine painful or difficult urination frequent and urgent need to urinate difficulty emptying bladder painful or swollen breasts More Common yellowing of the skin or eyes pain in the upper right part of the stomach extreme tiredness unusual bleeding or bruising lack of energy upset stomach loss of appetite flu-like symptoms dull or sharp side pain chest pain flatulence (passing gas) hair loss or decreased hair regrowth hot flashes impotence or reduction in sexual desire increased sensitivity of the skin to sun; increased risk of sunburn indigestion Rare abdominal pain blood in the urine chest pain severe itching signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath) signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide) signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools) symptoms of high blood sugar (e.g., frequent urination, increased thirst, excessive eating, unexplained weight loss, poor wound healing, infections, fruity breath odour) symptoms of heart failure (e.g., tiredness, shortness of breath especially when lying down, swelling of the feet or ankles) pain or tenderness in stomach signs of a heart attack (e.g., chest pain or pressure, pain extending through shoulder and arm, nausea and vomiting, sweating) symptoms of lung problems (e.g., shortness of breath, painful breathing, sudden shortness of breath, cough, fever) symptoms of a serious allergic reaction (e.g., hives, shortness of breath, difficulty swallowing, swelling of the face, lips, tongue or throat) Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Bicalutamide can be increased when it is combined with Abametapir. Abatacept The metabolism of Bicalutamide can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Bicalutamide. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Bicalutamide. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Bicalutamide. Acetaminophen The metabolism of Bicalutamide can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Bicalutamide can be decreased when combined with Acetazolamide. Adalimumab The metabolism of Bicalutamide can be increased when combined with Adalimumab. Albendazole The metabolism of Bicalutamide can be decreased when combined with Albendazole. Aldesleukin The metabolism of Bicalutamide can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Bicalutamide. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Bicalutamide. Alpelisib The metabolism of Bicalutamide can be increased when combined with Alpelisib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Bicalutamide. Aminoglutethimide The metabolism of Bicalutamide can be increased when combined with Aminoglutethimide. Aminophylline The metabolism of Aminophylline can be decreased when combined with Bicalutamide. Amiodarone The metabolism of Bicalutamide can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Bicalutamide. Amobarbital The metabolism of Bicalutamide can be increased when combined with Amobarbital. Amprenavir The metabolism of Bicalutamide can be decreased when combined with Amprenavir. Anakinra The metabolism of Bicalutamide can be increased when combined with Anakinra. Apalutamide The metabolism of Bicalutamide can be increased when combined with Apalutamide. Apremilast The metabolism of Bicalutamide can be increased when combined with Apremilast. Aprepitant The metabolism of Bicalutamide can be decreased when combined with Aprepitant. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Bicalutamide. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Bicalutamide. Armodafinil The metabolism of Bicalutamide can be increased when combined with Armodafinil. Articaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Articaine. Asciminib The serum concentration of Bicalutamide can be increased when it is combined with Asciminib. Astemizole The serum concentration of Astemizole can be increased when it is combined with Bicalutamide. Asunaprevir The metabolism of Bicalutamide can be increased when combined with Asunaprevir. Atazanavir The metabolism of Bicalutamide can be decreased when combined with Atazanavir. Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Bicalutamide. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Bicalutamide. Avacopan The metabolism of Bicalutamide can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Bicalutamide. Axitinib The metabolism of Axitinib can be decreased when combined with Bicalutamide. Azithromycin The metabolism of Bicalutamide can be decreased when combined with Azithromycin. Beclomethasone The metabolism of Bicalutamide can be increased when combined with Beclomethasone dipropionate. Belzutifan The serum concentration of Bicalutamide can be decreased when it is combined with Belzutifan. Benzocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Benzyl alcohol. Berotralstat The serum concentration of Bicalutamide can be increased when it is combined with Berotralstat. Betamethasone The metabolism of Bicalutamide can be increased when combined with Betamethasone. Betamethasone The metabolism of Bicalutamide can be increased when combined with Betamethasone phosphate. Bexarotene The metabolism of Bicalutamide can be increased when combined with Bexarotene. Bifonazole The metabolism of Bicalutamide can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Bicalutamide can be increased when combined with Bimekizumab. Boceprevir The metabolism of Bicalutamide can be decreased when combined with Boceprevir. Bortezomib The metabolism of Bortezomib can be decreased when combined with Bicalutamide. Bosentan The metabolism of Bicalutamide can be increased when combined with Bosentan. Bosutinib The metabolism of Bosutinib can be decreased when combined with Bicalutamide. Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Bicalutamide. Brigatinib The metabolism of Brigatinib can be decreased when combined with Bicalutamide. Budesonide The metabolism of Bicalutamide can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Bupivacaine. Buprenorphine The metabolism of Bicalutamide can be decreased when combined with Buprenorphine. Busulfan The metabolism of Busulfan can be decreased when combined with Bicalutamide. Butacaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Butacaine. Butalbital The metabolism of Bicalutamide can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Bicalutamide. Cabergoline The metabolism of Cabergoline can be decreased when combined with Bicalutamide. Calcitriol The metabolism of Bicalutamide can be increased when combined with Calcitriol. Canakinumab The metabolism of Bicalutamide can be increased when combined with Canakinumab. Candicidin The metabolism of Bicalutamide can be decreased when combined with Candicidin. Cannabidiol The metabolism of Bicalutamide can be decreased when combined with Cannabidiol. Capromab pendetide Bicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Capsaicin The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Capsaicin. Carbamazepine The metabolism of Bicalutamide can be increased when combined with Carbamazepine. Cefradine The metabolism of Bicalutamide can be increased when combined with Cefradine. Cenobamate The serum concentration of Bicalutamide can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Bicalutamide can be decreased when combined with Cephalexin. Ceritinib The metabolism of Ceritinib can be decreased when combined with Bicalutamide. Cerivastatin The metabolism of Bicalutamide can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Bicalutamide can be increased when combined with Certolizumab pegol. Chloramphenicol The metabolism of Bicalutamide can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Chloroprocaine. Chlorpromazine The metabolism of Bicalutamide can be increased when combined with Chlorpromazine. Choline C 11 Bicalutamide may decrease effectiveness of Choline C 11 as a diagnostic agent. Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Bicalutamide. Cimetidine The metabolism of Bicalutamide can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Cinchocaine. Ciprofloxacin The metabolism of Bicalutamide can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Bicalutamide can be decreased when combined with Cisapride. Citalopram The metabolism of Bicalutamide can be decreased when combined with Citalopram. Clarithromycin The metabolism of Bicalutamide can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Bicalutamide can be increased when combined with Clevidipine. Clobazam The metabolism of Bicalutamide can be increased when combined with Clobazam. Clobetasol propionate The metabolism of Bicalutamide can be increased when combined with Clobetasol propionate. Clofazimine The metabolism of Bicalutamide can be decreased when combined with Clofazimine. Clofibrate The metabolism of Bicalutamide can be increased when combined with Clofibrate. Clomipramine The metabolism of Clomipramine can be decreased when combined with Bicalutamide. Clonidine The metabolism of Clonidine can be decreased when combined with Bicalutamide. Clozapine The metabolism of Bicalutamide can be increased when combined with Clozapine. Cobicistat The metabolism of Bicalutamide can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Bicalutamide. Cocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Cocaine. Colchicine The metabolism of Colchicine can be decreased when combined with Bicalutamide. Conivaptan The metabolism of Bicalutamide can be decreased when combined with Conivaptan. Copanlisib The metabolism of Copanlisib can be decreased when combined with Bicalutamide. Corticotropin The metabolism of Bicalutamide can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Bicalutamide can be increased when combined with Cortisone acetate. Crizotinib The metabolism of Bicalutamide can be decreased when combined with Crizotinib. Curcumin The metabolism of Bicalutamide can be decreased when combined with Curcumin. Cyclophosphamide The metabolism of Bicalutamide can be increased when combined with Cyclophosphamide. Cyclosporine The metabolism of Bicalutamide can be decreased when combined with Cyclosporine. Cyproterone acetate The metabolism of Bicalutamide can be decreased when combined with Cyproterone acetate. Dabrafenib The serum concentration of Bicalutamide can be decreased when it is combined with Dabrafenib. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Bicalutamide. Dalfopristin The metabolism of Bicalutamide can be decreased when combined with Dalfopristin. Danazol The metabolism of Bicalutamide can be decreased when combined with Danazol. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bicalutamide. Darunavir The serum concentration of Bicalutamide can be increased when it is combined with Darunavir. Dasatinib The metabolism of Dasatinib can be decreased when combined with Bicalutamide. Daunorubicin The metabolism of Bicalutamide can be decreased when combined with Daunorubicin. Deferasirox The metabolism of Bicalutamide can be increased when combined with Deferasirox. Deflazacort The metabolism of Bicalutamide can be increased when combined with Deflazacort. Delavirdine The metabolism of Bicalutamide can be decreased when combined with Delavirdine. Desipramine The metabolism of Bicalutamide can be decreased when combined with Desipramine. Desvenlafaxine The metabolism of Bicalutamide can be decreased when combined with Desvenlafaxine. Dexamethasone The metabolism of Bicalutamide can be increased when combined with Dexamethasone. Dexamethasone acetate The metabolism of Bicalutamide can be increased when combined with Dexamethasone acetate. Dextropropoxyphene The metabolism of Bicalutamide can be decreased when combined with Dextropropoxyphene. Dicloxacillin The metabolism of Bicalutamide can be increased when combined with Dicloxacillin. Diethylstilbestrol The metabolism of Bicalutamide can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Bicalutamide can be increased when combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be decreased when combined with Bicalutamide. Dihydroergocornine The metabolism of Bicalutamide can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Bicalutamide can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Bicalutamide. Diltiazem The metabolism of Bicalutamide can be decreased when combined with Diltiazem. Dimethyl sulfoxide The metabolism of Bicalutamide can be decreased when combined with Dimethyl sulfoxide. Diosmin The metabolism of Bicalutamide can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Diphenhydramine. Docetaxel The metabolism of Docetaxel can be decreased when combined with Bicalutamide. Dofetilide The metabolism of Dofetilide can be decreased when combined with Bicalutamide. Doxazosin The metabolism of Bicalutamide can be decreased when combined with Doxazosin. Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Bicalutamide. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Bicalutamide. Dronedarone The serum concentration of Bicalutamide can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Bicalutamide can be decreased when combined with Drospirenone. Duvelisib The metabolism of Bicalutamide can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Dyclonine. Ebastine The metabolism of Bicalutamide can be decreased when combined with Ebastine. Echinacea The metabolism of Bicalutamide can be increased when combined with Echinacea. Efavirenz The metabolism of Bicalutamide can be decreased when combined with Efavirenz. Elexacaftor The metabolism of Bicalutamide can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Eliglustat can be decreased when combined with Bicalutamide. Elvitegravir The metabolism of Bicalutamide can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Bicalutamide can be increased when combined with Emapalumab. Enasidenib The metabolism of Bicalutamide can be increased when combined with Enasidenib. Entrectinib The metabolism of Entrectinib can be decreased when combined with Bicalutamide. Enzalutamide The serum concentration of Bicalutamide can be decreased when it is combined with Enzalutamide. Epinephrine The metabolism of Bicalutamide can be decreased when combined with Epinephrine. Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Bicalutamide. Ergotamine The metabolism of Bicalutamide can be decreased when combined with Ergotamine. Erlotinib The metabolism of Erlotinib can be decreased when combined with Bicalutamide. Erythromycin The metabolism of Bicalutamide can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bicalutamide. Esketamine The metabolism of Bicalutamide can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Bicalutamide can be increased when combined with Eslicarbazepine. Eslicarbazepine acetate The metabolism of Bicalutamide can be increased when combined with Eslicarbazepine acetate. Estetrol The metabolism of Bicalutamide can be decreased when combined with Estetrol. Estradiol acetate The metabolism of Bicalutamide can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Bicalutamide can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Bicalutamide can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Bicalutamide can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Bicalutamide can be increased when combined with Estradiol valerate. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Bicalutamide. Etanercept The metabolism of Bicalutamide can be increased when combined with Etanercept. Ethambutol The metabolism of Bicalutamide can be decreased when combined with Ethambutol. Ethanol The metabolism of Bicalutamide can be increased when combined with Ethanol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Bicalutamide. Etoricoxib The metabolism of Bicalutamide can be decreased when combined with Etoricoxib. Etravirine The metabolism of Bicalutamide can be increased when combined with Etravirine. Everolimus The metabolism of Everolimus can be decreased when combined with Bicalutamide. Felbamate The metabolism of Bicalutamide can be increased when combined with Felbamate. Fenofibrate The metabolism of Bicalutamide can be decreased when combined with Fenofibrate. Fentanyl The metabolism of Fentanyl can be decreased when combined with Bicalutamide. Fexinidazole The metabolism of Bicalutamide can be decreased when combined with Fexinidazole. Finerenone The serum concentration of Finerenone can be increased when it is combined with Bicalutamide. Flucloxacillin The metabolism of Bicalutamide can be increased when combined with Flucloxacillin. Fluconazole The metabolism of Bicalutamide can be decreased when combined with Fluconazole. Flunisolide The metabolism of Bicalutamide can be increased when combined with Flunisolide. Fluocinolone acetonide The metabolism of Bicalutamide can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Bicalutamide can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Bicalutamide can be increased when combined with Fluocortolone. Fluoxetine The metabolism of Bicalutamide can be decreased when combined with Fluoxetine. Fluticasone The metabolism of Bicalutamide can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Bicalutamide can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Bicalutamide can be decreased when combined with Fluticasone propionate. Fluvoxamine The metabolism of Bicalutamide can be decreased when combined with Fluvoxamine. Formestane The metabolism of Bicalutamide can be increased when combined with Formestane. Fosamprenavir The metabolism of Bicalutamide can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Bicalutamide can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Bicalutamide can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Bicalutamide can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Bicalutamide can be decreased when combined with Fostamatinib. Fusidic acid The metabolism of Bicalutamide can be decreased when combined with Fusidic acid. Gallium Ga-68 gozetotide Bicalutamide may increase effectiveness of Gallium Ga-68 gozetotide as a diagnostic agent. Gilteritinib The metabolism of Bicalutamide can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Bicalutamide can be decreased when combined with Ginkgo biloba. Glecaprevir The metabolism of Bicalutamide can be decreased when combined with Glecaprevir. Glyburide The metabolism of Bicalutamide can be decreased when combined with Glyburide. Glycerol phenylbutyrate The metabolism of Bicalutamide can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Bicalutamide can be increased when combined with Golimumab. Griseofulvin The metabolism of Bicalutamide can be increased when combined with Griseofulvin. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Bicalutamide. Hydralazine The metabolism of Bicalutamide can be decreased when combined with Hydralazine. Hydrocortamate The metabolism of Bicalutamide can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Bicalutamide can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Bicalutamide can be increased when combined with Hydrocortisone acetate. Hydrocortisone butyrate The metabolism of Bicalutamide can be increased when combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Bicalutamide can be increased when combined with Hydrocortisone succinate. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Bicalutamide. Idelalisib The metabolism of Idelalisib can be decreased when combined with Bicalutamide. Ifosfamide The metabolism of Bicalutamide can be increased when combined with Ifosfamide. Iloperidone The metabolism of Iloperidone can be decreased when combined with Bicalutamide. Imatinib The serum concentration of Bicalutamide can be increased when it is combined with Imatinib. Indinavir The metabolism of Bicalutamide can be decreased when combined with Indinavir. Infigratinib The metabolism of Bicalutamide can be decreased when combined with Infigratinib. Infliximab The metabolism of Bicalutamide can be increased when combined with Infliximab. Irbesartan The metabolism of Bicalutamide can be decreased when combined with Irbesartan. Irinotecan The metabolism of Irinotecan can be decreased when combined with Bicalutamide. Isavuconazole The metabolism of Bicalutamide can be increased when combined with Isavuconazole. Isavuconazonium The metabolism of Bicalutamide can be increased when combined with Isavuconazonium. Isoniazid The metabolism of Bicalutamide can be decreased when combined with Isoniazid. Isradipine The metabolism of Bicalutamide can be decreased when combined with Isradipine. Itraconazole The metabolism of Bicalutamide can be decreased when combined with Itraconazole. Ivacaftor The metabolism of Bicalutamide can be decreased when combined with Ivacaftor. Ivosidenib The metabolism of Bicalutamide can be increased when combined with Ivosidenib. Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Bicalutamide. Ixazomib The metabolism of Ixazomib can be decreased when combined with Bicalutamide. Ketazolam The metabolism of Bicalutamide can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Bicalutamide can be decreased when combined with Ketoconazole. Lacosamide The metabolism of Bicalutamide can be decreased when combined with Lacosamide. Lanreotide The metabolism of Bicalutamide can be decreased when combined with Lanreotide. Lapatinib The metabolism of Bicalutamide can be decreased when combined with Lapatinib. Lefamulin The serum concentration of Bicalutamide can be increased when it is combined with Lefamulin. Lesinurad The metabolism of Bicalutamide can be increased when combined with Lesinurad. Letermovir The metabolism of Bicalutamide can be decreased when combined with Letermovir. Levacetylmethadol The metabolism of Levacetylmethadol can be decreased when combined with Bicalutamide. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Bicalutamide. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Levobupivacaine. Levoketoconazole The metabolism of Bicalutamide can be decreased when combined with Levoketoconazole. Lidocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Lidocaine. Linagliptin The metabolism of Bicalutamide can be decreased when combined with Linagliptin. Lomitapide The metabolism of Lomitapide can be decreased when combined with Bicalutamide. Lonafarnib The metabolism of Bicalutamide can be decreased when combined with Lonafarnib. Lopinavir The metabolism of Bicalutamide can be decreased when combined with Lopinavir. Lorlatinib The metabolism of Bicalutamide can be increased when combined with Lorlatinib. Losartan The metabolism of Bicalutamide can be decreased when combined with Losartan. Lovastatin The metabolism of Lovastatin can be decreased when combined with Bicalutamide. Lumacaftor The metabolism of Bicalutamide can be increased when combined with Lumacaftor. Manidipine The metabolism of Bicalutamide can be decreased when combined with Manidipine. Mavacamten The serum concentration of Bicalutamide can be decreased when it is combined with Mavacamten. Medroxyprogesterone The metabolism of Bicalutamide can be increased when combined with Medroxyprogesterone acetate. Meloxicam The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Meloxicam. Meperidine The metabolism of Bicalutamide can be decreased when combined with Meperidine. Mepivacaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Mepivacaine. Meprednisone The metabolism of Bicalutamide can be increased when combined with Meprednisone. Methadone The metabolism of Bicalutamide can be decreased when combined with Methadone. Methimazole The metabolism of Bicalutamide can be decreased when combined with Methimazole. Methotrexate The metabolism of Methotrexate can be decreased when combined with Bicalutamide. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bicalutamide. Methylene blue The metabolism of Bicalutamide can be decreased when combined with Methylene blue. Methylergometrine The metabolism of Bicalutamide can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Bicalutamide can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Bicalutamide can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Bicalutamide can be decreased when combined with Methylprednisone. Methysergide The metabolism of Bicalutamide can be decreased when combined with Methysergide. Metreleptin The metabolism of Bicalutamide can be increased when combined with Metreleptin. Metronidazole The metabolism of Bicalutamide can be decreased when combined with Metronidazole. Metyrapone The metabolism of Bicalutamide can be increased when combined with Metyrapone. Miconazole The metabolism of Bicalutamide can be decreased when combined with Miconazole. Midazolam The serum concentration of Midazolam can be increased when it is combined with Bicalutamide. Midostaurin The metabolism of Bicalutamide can be decreased when combined with Midostaurin. Mifepristone The metabolism of Bicalutamide can be increased when combined with Mifepristone. Milnacipran The metabolism of Bicalutamide can be decreased when combined with Milnacipran. Miocamycin The metabolism of Bicalutamide can be decreased when combined with Miocamycin. Mirtazapine The metabolism of Bicalutamide can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Bicalutamide can be increased when combined with Mitapivat. Mitotane The metabolism of Bicalutamide can be increased when combined with Mitotane. Mobocertinib The serum concentration of Bicalutamide can be decreased when it is combined with Mobocertinib. Modafinil The metabolism of Bicalutamide can be increased when combined with Modafinil. Mometasone furoate The metabolism of Bicalutamide can be increased when combined with Mometasone furoate. Mosunetuzumab The metabolism of Bicalutamide can be decreased when combined with Mosunetuzumab. Nafcillin The metabolism of Bicalutamide can be increased when combined with Nafcillin. Naloxone The metabolism of Bicalutamide can be decreased when combined with Naloxone. Nefazodone The metabolism of Bicalutamide can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Bicalutamide can be decreased when combined with Nelfinavir. Neratinib The metabolism of Neratinib can be decreased when combined with Bicalutamide. Netupitant The metabolism of Bicalutamide can be decreased when combined with Netupitant. Niacin The metabolism of Bicalutamide can be decreased when combined with Niacin. Nicardipine The metabolism of Bicalutamide can be decreased when combined with Nicardipine. Nilotinib The metabolism of Bicalutamide can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Bicalutamide can be decreased when combined with Nilvadipine. Nintedanib The metabolism of Bicalutamide can be decreased when combined with Nintedanib. Norethisterone The metabolism of Bicalutamide can be decreased when combined with Norethisterone. Norgestimate The metabolism of Bicalutamide can be increased when combined with Norgestimate. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Bicalutamide. Noscapine The metabolism of Bicalutamide can be decreased when combined with Noscapine. Octreotide The serum concentration of Bicalutamide can be increased when it is combined with Octreotide. Olaparib The metabolism of Olaparib can be decreased when combined with Bicalutamide. Omeprazole The metabolism of Bicalutamide can be increased when combined with Omeprazole. Oritavancin The metabolism of Bicalutamide can be increased when combined with Oritavancin. Orphenadrine The metabolism of Bicalutamide can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Bicalutamide can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Osimertinib can be decreased when combined with Bicalutamide. Oxcarbazepine The metabolism of Bicalutamide can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Oxybuprocaine. Oxybutynin The metabolism of Bicalutamide can be decreased when combined with Oxybutynin. Paclitaxel The metabolism of Bicalutamide can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Bicalutamide can be increased when it is combined with Pacritinib. Palbociclib The metabolism of Palbociclib can be decreased when combined with Bicalutamide. Panobinostat The metabolism of Panobinostat can be decreased when combined with Bicalutamide. Pasireotide The metabolism of Bicalutamide can be decreased when combined with Pasireotide. Pazopanib The metabolism of Pazopanib can be decreased when combined with Bicalutamide. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bicalutamide. Pentobarbital The metabolism of Bicalutamide can be increased when combined with Pentobarbital. Perampanel The metabolism of Bicalutamide can be increased when combined with Perampanel. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Bicalutamide. Phenobarbital The metabolism of Bicalutamide can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Bicalutamide. Phenylbutazone The metabolism of Bicalutamide can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Bicalutamide can be increased when combined with Phenytoin. Piflufolastat F 18 Bicalutamide may decrease effectiveness of Piflufolastat F 18 as a diagnostic agent. Pimavanserin The metabolism of Bicalutamide can be decreased when combined with Pimavanserin. Pimozide The metabolism of Pimozide can be decreased when combined with Bicalutamide. Piperaquine The metabolism of Bicalutamide can be decreased when combined with Piperaquine. Pitolisant The serum concentration of Bicalutamide can be decreased when it is combined with Pitolisant. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Bicalutamide. Ponatinib The metabolism of Ponatinib can be decreased when combined with Bicalutamide. Posaconazole The metabolism of Bicalutamide can be decreased when combined with Posaconazole. Pralsetinib The metabolism of Bicalutamide can be increased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Pramocaine. Prednisolone The metabolism of Bicalutamide can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Bicalutamide can be increased when combined with Prednisolone acetate. Prednisolone phosphate The metabolism of Bicalutamide can be increased when combined with Prednisolone phosphate. Prednisone acetate The metabolism of Bicalutamide can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Bicalutamide can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Prilocaine. Primaquine The metabolism of Bicalutamide can be decreased when combined with Primaquine. Primidone The metabolism of Bicalutamide can be increased when combined with Primidone. Probenecid The metabolism of Bicalutamide can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Procaine. Proparacaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Proparacaine. Propofol The metabolism of Bicalutamide can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Propoxycaine. Propranolol The serum concentration of Propranolol can be increased when it is combined with Bicalutamide. Prucalopride The metabolism of Prucalopride can be decreased when combined with Bicalutamide. Quinidine The metabolism of Bicalutamide can be decreased when combined with Quinidine. Quinine The metabolism of Bicalutamide can be increased when combined with Quinine. Quinupristin The metabolism of Bicalutamide can be decreased when combined with Quinupristin. Raloxifene The metabolism of Bicalutamide can be decreased when combined with Raloxifene. Ranolazine The metabolism of Bicalutamide can be decreased when combined with Ranolazine. Regorafenib The metabolism of Regorafenib can be decreased when combined with Bicalutamide. Remdesivir The metabolism of Bicalutamide can be decreased when combined with Remdesivir. Retapamulin The metabolism of Retapamulin can be decreased when combined with Bicalutamide. Ribociclib The metabolism of Bicalutamide can be decreased when combined with Ribociclib. Rifabutin The metabolism of Bicalutamide can be increased when combined with Rifabutin. Rifampicin The metabolism of Bicalutamide can be increased when combined with Rifampicin. Rifamycin The metabolism of Bicalutamide can be increased when combined with Rifamycin. Rifapentine The metabolism of Bicalutamide can be increased when combined with Rifapentine. Rilonacept The metabolism of Bicalutamide can be increased when combined with Rilonacept. Rilpivirine The metabolism of Bicalutamide can be decreased when combined with Rilpivirine. Ritonavir The serum concentration of Bicalutamide can be increased when it is combined with Ritonavir. Rofecoxib The metabolism of Bicalutamide can be increased when combined with Rofecoxib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Bicalutamide. Romidepsin The metabolism of Romidepsin can be decreased when combined with Bicalutamide. Ropivacaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Ropivacaine. Rosuvastatin The metabolism of Bicalutamide can be decreased when combined with Rosuvastatin. Roxithromycin The metabolism of Bicalutamide can be decreased when combined with Roxithromycin. Rucaparib The metabolism of Bicalutamide can be decreased when combined with Rucaparib. Rufinamide The metabolism of Bicalutamide can be increased when combined with Rufinamide. Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Bicalutamide. Saquinavir The metabolism of Bicalutamide can be decreased when combined with Saquinavir. Sarilumab The metabolism of Bicalutamide can be increased when combined with Sarilumab. Satralizumab The serum concentration of Bicalutamide can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Bicalutamide can be increased when combined with Secobarbital. Secukinumab The metabolism of Bicalutamide can be increased when combined with Secukinumab. Siltuximab The metabolism of Bicalutamide can be increased when combined with Siltuximab. Simeprevir The metabolism of Bicalutamide can be decreased when combined with Simeprevir. Siponimod The metabolism of Siponimod can be decreased when combined with Bicalutamide. Sirolimus The metabolism of Sirolimus can be decreased when combined with Bicalutamide. Sitaxentan The metabolism of Bicalutamide can be decreased when combined with Sitaxentan. Somatostatin The metabolism of Bicalutamide can be decreased when combined with Somatostatin. Somatrogon The metabolism of Bicalutamide can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Bicalutamide. Sorafenib The metabolism of Sorafenib can be decreased when combined with Bicalutamide. Sotorasib The serum concentration of Bicalutamide can be decreased when it is combined with Sotorasib. St. John’s Wort The metabolism of Bicalutamide can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Bicalutamide can be decreased when combined with Stiripentol. Sulfamethoxazole The metabolism of Bicalutamide can be decreased when combined with Sulfamethoxazole. Sulfinpyrazone The metabolism of Bicalutamide can be increased when combined with Sulfinpyrazone. Sunitinib The metabolism of Sunitinib can be decreased when combined with Bicalutamide. Suvorexant The metabolism of Bicalutamide can be decreased when combined with Suvorexant. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Bicalutamide. Tamoxifen The metabolism of Bicalutamide can be increased when combined with Tamoxifen. Tasimelteon The metabolism of Bicalutamide can be decreased when combined with Tasimelteon. Tazemetostat The metabolism of Bicalutamide can be decreased when combined with Tazemetostat. Tecovirimat The metabolism of Bicalutamide can be increased when combined with Tecovirimat. Telaprevir The metabolism of Bicalutamide can be decreased when combined with Telaprevir. Telithromycin The metabolism of Bicalutamide can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Bicalutamide can be decreased when it is combined with Telotristat ethyl. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Bicalutamide. Teniposide The metabolism of Teniposide can be decreased when combined with Bicalutamide. Tenofovir alafenamide The metabolism of Bicalutamide can be decreased when combined with Tenofovir alafenamide. Terbinafine The metabolism of Bicalutamide can be increased when combined with Terbinafine. Terfenadine The serum concentration of Terfenadine can be increased when it is combined with Bicalutamide. Testosterone The metabolism of Bicalutamide can be increased when combined with Testosterone. Tetracaine The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Tetracaine. Tetracycline The metabolism of Bicalutamide can be decreased when combined with Tetracycline. Theophylline The metabolism of Theophylline can be decreased when combined with Bicalutamide. Thiamylal The metabolism of Bicalutamide can be increased when combined with Thiamylal. Thiotepa The metabolism of Thiotepa can be decreased when combined with Bicalutamide. Ticagrelor The metabolism of Bicalutamide can be decreased when combined with Ticagrelor. Timolol The metabolism of Timolol can be decreased when combined with Bicalutamide. Tipranavir The metabolism of Bicalutamide can be decreased when combined with Tipranavir. Tocilizumab The metabolism of Bicalutamide can be increased when combined with Tocilizumab. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Bicalutamide. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Bicalutamide. Topiramate The metabolism of Bicalutamide can be increased when combined with Topiramate. Trabectedin The metabolism of Trabectedin can be decreased when combined with Bicalutamide. Tramadol The metabolism of Tramadol can be decreased when combined with Bicalutamide. Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Bicalutamide. Triamcinolone The metabolism of Bicalutamide can be increased when combined with Triamcinolone. Triclabendazole The metabolism of Bicalutamide can be decreased when combined with Triclabendazole. Troglitazone The metabolism of Bicalutamide can be increased when combined with Troglitazone. Troleandomycin The metabolism of Bicalutamide can be decreased when combined with Troleandomycin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Bicalutamide. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Bicalutamide. Valproic acid The metabolism of Bicalutamide can be decreased when combined with Valproic acid. Vandetanib The metabolism of Vandetanib can be decreased when combined with Bicalutamide. Vardenafil The metabolism of Vardenafil can be decreased when combined with Bicalutamide. Vemurafenib The metabolism of Bicalutamide can be increased when combined with Vemurafenib. Venetoclax The metabolism of Bicalutamide can be decreased when combined with Venetoclax. Verapamil The metabolism of Bicalutamide can be decreased when combined with Verapamil. Viloxazine The metabolism of Bicalutamide can be decreased when combined with Viloxazine. Vinblastine The metabolism of Bicalutamide can be increased when combined with Vinblastine. Vincristine The metabolism of Vincristine can be decreased when combined with Bicalutamide. Vindesine The metabolism of Vindesine can be decreased when combined with Bicalutamide. Vinflunine The metabolism of Vinflunine can be decreased when combined with Bicalutamide. Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Bicalutamide. Vitamin E The metabolism of Bicalutamide can be increased when combined with Vitamin E. Vorapaxar The metabolism of Bicalutamide can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Bicalutamide can be decreased when combined with Voriconazole. Voxelotor The serum concentration of Bicalutamide can be increased when it is combined with Voxelotor. Warfarin The serum concentration of Warfarin can be increased when it is combined with Bicalutamide. Zafirlukast The metabolism of Bicalutamide can be decreased when combined with Zafirlukast. Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Bicalutamide. Zimelidine The metabolism of Bicalutamide can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Bicalutamide can be decreased when combined with Ziprasidone. Zopiclone The metabolism of Zopiclone can be decreased when combined with Bicalutamide. Zuclopenthixol The metabolism of Bicalutamide can be decreased when combined with Zuclopenthixol. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy This drug is contraindicated in females. This drug is contraindicated in pregnant women because it can cause fetal harm. Drugs that have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. Breastfeeding This drug is contraindicated in females; therefore, it is contraindicated in lactation. Excreted into human milk: Unknown Excreted into animal milk: Yes The effects in the nursing infant are unknown. How should this medicine be used? Bicalutamide comes as a tablet to take by mouth. It is usually taken with or without food once a day, either in the morning or evening. Take bicalutamide at around the same time every day. You should begin taking bicalutamide on the same day you begin injecting the luteinizing hormone-releasing hormone. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take bicalutamide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Bicalutamide along with the luteinizing hormone-releasing hormone may help stop the growth and spread of cancer cells but does not cure prostate cancer. Continue to take both bicalutamide and the luteinizing hormone-releasing hormone even if you feel better. Do not stop taking these medications without talking to your doctor. What special precautions should I follow? Before taking bicalutamide, tell your doctor and pharmacist if you are allergic to bicalutamide, any other medications, or any of the ingredients in bicalutamide tablets. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: alprazolam (Xanax); anticoagulants (‘blood thinners’) such as warfarin (Coumadin); aripiprazole (Abilify); buspirone (Buspar); calcium channel blockers such as amlodipine (Norvasc), diltiazem (Cardizem, Dilacor, Tiazac), felodipine (Plendil), nifedipine (Adalat, Procardia), nisoldipine (Sular), and verapamil (Calan, Covera, Isoptin, Verelan); chlorpheniramine; cholesterol-lowering medications (statins) such as atorvastatin (Lipitor), lovastatin (Mevacor), and simvastatin (Zocor); clarithromycin (Biaxin); cyclosporine (Neoral, Sandimmune); diazepam (Valium); erythromycin (E.E.S., E-Mycin, Erythrocin); HIV protease inhibitors such as indinavir (Crixivan), ritonavir (Norvir), and saquinavir (Invirase, Fortovase); methadone (Dolophine); midazolam (Versed); pimozide (Orap); quinidine (Quinidex, Quinaglute); quinine; sildenafil (Viagra); tacrolimus (Prograf); tamoxifen (Nolvadex); telithromycin (Ketek); trazodone (Desyrel); triazolam (Halcion); and vincristine (Vincasar). Many other medications may also interact with bicalutamide, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you have or have ever had liver disease. you should know that bicalutamide is only for use in men. If taken by pregnant women, bicalutamide can cause abnormalities in the fetus. Women who are or may become pregnant should not take bicalutamide. If you take bicalutamide while you are pregnant, call your doctor immediately. Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use this medication. Abnormal heart rhythm: Bicalutamide can cause changes to the normal rhythm of the heart, called QT prolongation. QT prolongation is a serious life-threatening condition. If you are at risk for heart rhythm problems (e.g., have heart failure, angina, low potassium or magnesium levels; have congenital long QT syndrome; or are taking medications that can prolong the QT interval, such as quinidine, procainamide, amiodarone, sotalol, flecainide), discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Anemia: Bicalutamide may cause low levels of red blood cells. If you experience symptoms of reduced red blood cell count (anemia) such as shortness of breath, feeling unusually tired, or pale skin, contact your doctor as soon as possible. Your doctor will do blood tests regularly to monitor the number of specific types of blood cells, including red blood cells, in your blood. Diabetes: Bicalutamide may cause an increase in blood sugar levels. People with diabetes may find it necessary to monitor their blood sugar more frequently while using this medication. If you have diabetes or are at risk for developing diabetes, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Drowsiness/reduced alertness: This medication may cause drowsiness. Do not drive, operate machinery, or perform other hazardous tasks until you have determined how this medication affects you. Heart disease: The risk of heart attack or heart failure is increased for people taking bicalutamide. If you have risk factors for heart disease (obesity, high blood cholesterol, smoking), discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Liver function: Bicalutamide is broken down by the liver. Liver disease or reduced liver function may cause this medication to build up in the body, causing side effects. If you have liver problems, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Your doctor may want to test your liver function regularly with blood tests while you are taking this medication. This medication may also cause liver problems. Contact your doctor immediately if you experience symptoms of liver problems such as fatigue, feeling unwell, loss of appetite, nausea, yellowing of the skin or whites of the eyes, dark urine, pale stools, abdominal pain or swelling, and itchy skin. Lung disease: Rarely, and particularly when higher doses are used, cases of interstitial lung disease have been reported with this medication. If you experience any symptoms of lung problems such as breathing difficulties, wheezing, cough, fever, or shortness of breath, contact your doctor immediately. Osteoporosis: Long-term use of bicalutamide has been shown to cause reduced bone strength and may increase the risk of bone fractures. If you have osteoporosis or are at increased risk of developing osteoporosis, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Sensitivity to sunlight: This medication may increase the sensitivity of the skin to sunlight, increasing the risk of sunburn. Avoid exposure to sunlight for long periods of time, particularly between the hours of 10 am and 2 pm, while you are taking this medication and for 7 days after completing treatment. Wear a broad-spectrum sunscreen and lip balm with an SPF of 50 or greater. If you notice any unusual skin rash or peeling, contact your doctor immediately. Children: The safety and effectiveness of this medication have not been determined for children. References https://pubchem.ncbi.nlm.nih.gov/compound/Bicalutamide https://go.drugbank.com/drugs/DB01128 https://medlineplus.gov/druginfo/meds/a697047.html https://www.webmd.com/drugs/2/drug-1554/bicalutamide-oral/details/list-contraindications https://www.drugs.com/bicalutamide.html https://www.medbroadcast.com/drug/getdrug/bicalutamide ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL409/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=C053541 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/BICALUTAMIDE DrugBank https://www.drugbank.ca/legal/terms_of_use Bicalutamide https://www.drugbank.ca/drugs/DB01128 IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2863 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Bicalutamide http://idrblab.net/ttd/data/drug/details/D0V9BD CAS Common Chemistry LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc/4.0/ Bicalutamide https://commonchemistry.cas.org/detail?cas_rn=90357-06-5 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Bicalutamide [USAN:USP:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0090357065 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DTP/NCI https://www.cancer.gov/policies/copyright-reuse bicalutamide https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=759816 bicalutamide https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=722665 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Bicalutamide https://comptox.epa.gov/dashboard/DTXSID2022678 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking BICALUTAMIDE https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A0Z3NAU9DP Hazardous Substances Data Bank (HSDB) BICALUTAMIDE https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7655 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Bicalutamide http://www.hmdb.ca/metabolites/HMDB0015260 HMDB0015260_msms_2231434 https://hmdb.ca/metabolites/HMDB0015260#spectra ChEBI N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:144093 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking BICALUTAMIDE https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Bicalutamide https://www.ncbi.nlm.nih.gov/books/n/livertox/Bicalutamide/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1599 NCI Thesaurus Tree https://ncit.nci.nih.gov ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html BICALUTAMIDE https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=BICALUTAMIDE Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking bicalutamide https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/98856 FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking BICALUTAMIDE https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NIST Mass Spectrometry Data Center LICENSE https://www.nist.gov/srd/public-law Bicalutamide http://www.nist.gov/srd/nist1a.cfm MassBank Europe LICENSE https://github.com/MassBank/MassBank-web/blob/main/MassBank-Project/LICENSE.txt LKJPYSCBVHEWIU-UHFFFAOYSA-N https://massbank.eu/MassBank/Result.jsp?inchikey=LKJPYSCBVHEWIU-UHFFFAOYSA-N MassBank of North America (MoNA) LICENSE The content of the MoNA database is licensed under CC BY 4.0. https://mona.fiehnlab.ucdavis.edu/documentation/license Bicalutamide https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22LKJPYSCBVHEWIU-UHFFFAOYSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Bicalutamide https://www.cancer.gov/about-cancer/treatment/drugs/bicalutamide NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ PubChem https://pubchem.ncbi.nlm.nih.gov PFAS and Fluorinated Compounds in PubChem https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=29052972-396921896 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=29052972-396921896 https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=29052972-396922230 WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Bicalutamide https://list.essentialmeds.org/medicines/112 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Bicalutamide https://www.wikidata.org/wiki/Q1988832 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html bicalutamide https://www.ncbi.nlm.nih.gov/mesh/67053541 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Androgen Antagonists https://www.ncbi.nlm.nih.gov/mesh/68000726 Antineoplastic Agents https://www.ncbi.nlm.nih.gov/mesh/68000970 KEGG https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg Drug Classes http://www.genome.jp/kegg-bin/get_htext?br08332.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html EPA Substance Registry Services LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources EPA SRS List Classification https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do PATENTSCOPE (WIPO) SID 391015320 https://pubchem.ncbi.nlm.nih.gov/substance/391015320 SID 403614838 https://pubchem.ncbi.nlm.nih.gov/substance/403614838 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More